IMCC IM Cannabis Corp. IFRS
Medicinal Chemicals & Botanical Products · Nasdaq · SEC CIK 1792030 · Reporting currency CAD · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (FY2025), by fiscal year; growth vs the previous fiscal year
Growth
Margins
Returns
Leverage & solvency
Cash quality & payout
Factor history charts and full statement history on Pro 🔒
Financial statements
| Unit: CAD | 2025Q22025-06-30 | 2024Q22024-06-30 | 2023Q22023-06-30 | 2022Q22022-06-30 | 2021Q22021-06-30 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | 12.70M | 14.75M | 13.21M | 12.70M | 11.11M |
| Cost of revenue | 9.27M | 13.91M | 9.47M | 10.11M | 10.51M |
| Gross profit | 3.42M | 844,000 | 3.46M | 2.20M | -568,000 |
| SG&A expense | 2.48M | 2.16M | 2.39M | 3.34M | 7.47M |
| Operating income | -350,000 | -2.87M | -1.75M | -5.62M | -10.72M |
| Interest expense | 1.76M | 1.46M | 2.11M | 2.20M | 543,000 |
| Pretax income | -220,000 | -4.29M | -3.87M | -4.71M | -5.05M |
| Income tax | -26,000 | -839,000 | -160,000 | -1.01M | 37,000 |
| Net income | -309,000 | -3.03M | -3.46M | -18.66M | -4.63M |
| EBITDA | — | -2.36M | -974,000 | -4.78M | — |
| EPS (basic) | -0.09 | -1.36 | -0.26 | -2.72 | -0.10 |
| EPS (diluted) | -0.09 | -1.36 | -0.26 | -3.12 | -0.23 |
| Weighted avg. shares (diluted) | — | — | — | 71.71M | 45.62M |
| Balance sheet | |||||
| Cash & equivalents | 794,000 | 700,000 | 1.32M | 5.86M | 34.05M |
| Receivables | 12.52M | 3.65M | 3.40M | 6.17M | — |
| Inventory | 3.66M | 5.72M | 14.48M | 26.65M | — |
| Current assets | 25.44M | 22.94M | 30.40M | 63.32M | — |
| PP&E, netmay include right-of-use assets (IFRS) | 3.81M | 4.05M | 5.24M | 22.67M | — |
| Goodwill | 6.86M | 6.63M | 9.10M | 117.22M | — |
| Intangibles | 2.82M | 3.68M | 6.57M | 26.72M | — |
| Total assets | 41.07M | 40.22M | 55.75M | 255.31M | — |
| Current liabilities | 35.15M | 33.40M | 28.11M | 53.56M | — |
| Short-term debt | 13.32M | 12.75M | 11.48M | 18.00M | — |
| Long-term debt | 1.30M | 401,000 | 379,000 | 354,000 | — |
| Total debt | 14.62M | 13.15M | 11.86M | 18.36M | — |
| Total liabilities | 37.01M | 34.73M | 34.21M | 75.76M | — |
| Shareholders' equity | 3.52M | 7.07M | 20.91M | 177.56M | 143.63M |
| Net debt | 13.83M | 12.45M | 10.54M | 12.49M | — |
| Shares outstanding | 4.04M | 13.39M | 13.39M | 69.70M | — |
| Cash flow statement | |||||
| Operating cash flow | — | — | — | — | — |
| Depreciation & amortization | — | 511,000 | 778,000 | 847,000 | — |
| Stock-based compensation | 4,000 | 88,000 | -137,000 | 732,000 | 1.37M |
· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· Amounts are in the company's reporting currency, CAD, not USD; the site does no currency conversion.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.